Bears, beets, rifaximin

. 2021 Nov 11;4(4):438-442.

doi: 10.3138/canlivj-2021-0026. eCollection 2021 Fall.

Peter L Wang¹, Jennifer A Flemming^{1

2}

Affiliations

¹ Department of Medicine, Queen's University, Kingston, Ontario, Canada.
² Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada.

Peter L Wang et al. Can Liver J. 2021.

. 2021 Nov 11;4(4):438-442.

doi: 10.3138/canlivj-2021-0026. eCollection 2021 Fall.

Peter L Wang¹, Jennifer A Flemming^{1

2}

¹ Department of Medicine, Queen's University, Kingston, Ontario, Canada.
² Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada.

No abstract available

Keywords: hepatic encephalopathy; rifaximin; TIPS.

Conflict of interest statement

The authors have nothing to disclose.

1. Calanni F, Renzulli C, Barbanti M, Viscomi GC. Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo). 2014;67(9): 667–70. 10.1038/ja.2014.106. Medline: - DOI - PubMed
1. Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol. 2010; 26(1):17–25. 10.1097/MOG.0b013e328333dc8d. Medline: - DOI - PMC - PubMed
1. Mas A, Rodés J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003; 38(1):51–8. 10.1016/S0168-8278(02)00350-1. Medline: - DOI - PubMed
1. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. New Engl J Med. 2010;362(12):1071–81. 10.1056/NEJMoa0907893. Medline: - DOI - PubMed
1. Sarwar S, Muhyuddin B, Aleem A, Nadeem MA. Primary prophylaxis of hepatic encephalopathy in decompensated cirrhosis: low dose vs. full dose rifaximin. Pak J Med Sci. 2019;35(5):1446–50. 10.12669/pjms.35.5.549. Medline: - DOI - PMC - PubMed